Annotation Detail

Information
Associated Genes
BTK
Associated Variants
BTK p.Cys515Ser (p.C515S) ( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 )
BTK p.Cys515Ser (p.C515S) ( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 )
Associated Disease
chronic lymphocytic leukemia
Source Database
CIViC Evidence
Description
Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/436
Gene URL
https://civic.genome.wustl.edu/links/genes/65
Variant URL
https://civic.genome.wustl.edu/links/variants/168
Rating
4
Evidence Type
Predictive
Disease
Chronic Lymphocytic Leukemia
Evidence Direction
Supports
Drug
Ibrutinib
Evidence Level
B
Clinical Significance
Resistance
Pubmed
24869598
Drugs
Drug NameSensitivitySupported
IbrutinibResitance or Non-Reponsetrue